Document is current
Any future updates will be listed below
-
Authors
Tagliapietra, Matteo https://orcid.org/0000-0002-3048-1453
Cardellini, Davide
Ferrarini, Moreno https://orcid.org/0000-0001-8768-7922
Testi, Silvia https://orcid.org/0000-0003-0267-0000
Ferrari, Sergio https://orcid.org/0000-0003-3855-5135
Monaco, Salvatore https://orcid.org/0000-0003-3191-8597
Cavallaro, Tiziana https://orcid.org/0000-0002-7851-6408
Fabrizi, Gian Maria https://orcid.org/0000-0001-6804-0226
-
Funding
Funding for this research was provided by:
Akcea
Università degli Studi di Verona
- License Information
-
More Information
Article History
Received: 18 March 2021
Revised: 1 April 2021
Accepted: 8 April 2021
First Online: 21 April 2021
Declarations
:
: M. Tagliapietra reports a training grant from Pfizer and received support for attending scientific meetings from Alnylam. S. Ferrari received support for attending scientific meetings from Sanofi-Genzyme, Merck and Euroimmun. G.M. Fabrizi served on Advisory Boards for Alnylam, Akcea and Pharnext-Vitaccess, received speaker fees from Akcea and support for attending scientific meetings by Pfizer and Akcea. D. Cardellini, M. Ferrarini, S. Testi, S. Monaco and T. Cavallaro report no disclosures.
: This retrospective study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the local Bioethics Committee (Comitato Etico per la Sperimentazione Clinica, Azienda Ospedaliera Universitaria Integrata di Verona) (BIOB-NEU-DNA-2014, protocol 13582).
: Written informed consent for future research was obtained from all participants at the time of biopsy.
